IL33 and chronic obstructive pulmonary disease: Using FCM as a tool, it has been described that COPD patients have high concentrations of IL-33 (alarmin) in the bloodstream, favouring the generation of autoantibodies directed against type II alveolar epithelial cells, and consequently there is damage to lung tissue [49].